CERebrolysin in CADASIL

Phase 2

Active, not recruiting

• Conditions: Cadasil
• Interventions: Drug: Cerebrolysin; Drug: 0.9 % NaCl

• Registration Number: NCT05755997
• Lead Sponsor: Ever Neuro Pharma GmbH

Brief Summary

The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL. In addition, a traditional approach will be taken based on an evaluation of the separate risk and benefit domains in comparison with placebo.

Detailed Description

Safety data area collected throughout the study (adverse events, vital signs and laboratory tests) and thereafter in case of ongoing serious adverse events (SAEs) at study endpoint.

Optional secondary parameters include analyses of biomarkers (samples of blood, hair, urine, and saliva).

Study Timeline

• Study First Submitted: 2023-02-14
• Study First Submitted QC: 2023-02-23
• Study First Posted: 2023-03-06
• Study Start: 2023-11-29
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-24
• Last Update Posted: 2025-02-25
• Primary Completion: 2026-03-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Patients of ≥18 years of age, all genders
2. Diagnosis of CADASIL based on clinical symptoms, MRI, and genetic analysis
3. MoCA >11
4. Adequate visual, auditory, and language skills (no language interpreter required) to follow study procedures
5. Patient is not of childbearing potential (i.e. women are post-menopausal for two years, surgically sterile, or using adequate method of contraception)
6. Patient participates voluntarily and gave written informed consent

Exclusion Criteria

1. Any significant neurological disease/conditions other than CADASIL

2. Focal lesions that may be responsible for the cognitive status of the patient (e.g.

   infectious disease, space-occupying lesion, normal pressure hydrocephalus)

3. Any other diseases/conditions that may affect compliance with the protocol, such as:

   1. severe psychiatric disorders within the last three months
   2. delusional symptoms
   3. history of schizophrenia, schizoaffective disorder, bipolar affective disorder
   4. major depressive disorder newly identified within eight weeks before screening
   5. history of alcohol or substance abuse or dependence within the past two years

4. Any circumstances that -in the investigator's opinion- may result in the patient's non-compliance with study procedures, e.g. fragile or thin veins that prevent many i.v. infusions

5. Any other disease/conditions that may affect the safety assessment, such as:

   1. history of systemic cancer within the past two years
   2. history of myocardial infarction in the past year or unstable or severe cardiovascular disease (including uncontrolled hypertension and/or history of unstable hypertension not compensated by antihypertensive therapy)
   3. any clinically significant laboratory abnormalities at screening
   4. uncontrolled insulin-requiring diabetes or non-insulin dependent diabetes mellitus (HbA1c >87 mmol/mol)

6. Use of concomitant medication with neuroprotective/neurotrophic/nootropic effects (e.g. ginkgo biloba, erythropoietin, citicoline, amantadine, piracetam)

7. Any condition that would represent a contraindication for Cerebrolysin administration:

   1. hypersensitivity to one of the components of the drug
   2. epilepsy
   3. severe renal impairment (estimated Glomerular Filtration Rate [eGFR] <30 ml/min/1.73 m2 as assessed at local laboratory within one month before screening)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Study group 1	Cerebrolysin	Cerebrolysin - Placebo
Study group 1	0.9 % NaCl	Cerebrolysin - Placebo
Study group 2	Cerebrolysin	Placebo - Cerebrolysin
Study group 2	0.9 % NaCl	Placebo - Cerebrolysin

Primary Outcome Measures

Name	Time	Method
Change in cognitive battery (RAVLT)	Baseline, Month 6, Month 12, Month 21, Month 27	- Rey Auditory Verbal Learning Test (AVLT)
Change in cognitive battery (ROCF: Copy, immediate recall)	Baseline, Month 6, Month 12, Month 21, Month 27	- Rey-Osterrieth Complex Figure Test (ROCF): Copy, immediate recall
Change in cognitive battery (Digit Symbol Coding, subscale of WAIS-PSI)	Baseline, Month 6, Month 12, Month 21, Month 27	- Digit Symbol Coding (subscale of WAIS-PSI)
Change in cognitive battery (Digit Span: Digit backward (subscale of WAIS-WMI)	Baseline, Month 6, Month 12, Month 21, Month 27	- Digit Span: Digit backward (subscale of WAIS-WMI)
Change in cognitive battery (Trail Making Test, Part B)	Baseline, Month 6, Month 12, Month 21, Month 27	- Trail Making Test (Part B)
Change in cognitive battery (ROCF: Delayed recall)	Baseline, Month 6, Month 12, Month 21, Month 27	- Rey-Osterrieth Complex Figure Test (ROCF): Delayed recall
Change in cognitive battery (Stroop Color and Word Test - Prague Version)	Baseline, Month 6, Month 12, Month 21, Month 27	- Stroop Color and Word Test - Prague Version (word/dots interference)
Change in cognitive battery (MoCA)	Baseline, Month 6, Month 12, Month 21, Month 27	- Montreal Cognitive Assessment (MoCA)
Change in mood (Beck Depression Inventory-II)	Baseline, Month 6, Month 12, Month 21, Month 27	- Beck Depression Inventory-II (BDI-II)
Change in imaging (White matter lesion volume)	Baseline, Month 12, Month 27	- White matter lesion volume (MRI)

Secondary Outcome Measures

Name	Time	Method
Change in cognitive battery, secondary outcome (Trail Making Test, Part A)	Baseline, Month 6, Month 12, Month 21, Month 27	- Trail Making Test (Part A)
Change in cognitive battery, secondary outcome (Symbol Search, subscale of WAIS-PSI)	Baseline, Month 6, Month 12, Month 21, Month 27	- Symbol Search (subscale of WAIS-PSI)
Change in mood, secondary outcome (Beck Anxiety Inventory)	Baseline, Month 6, Month 12, Month 21, Month 27	- Beck Anxiety Inventory
Change in neurological deficits, secondary outcome (NIH stroke scale)	Baseline, Month 6, Month 12, Month 21, Month 27	- NIH stroke scale (NIHSS)
Change in imaging, secondary outcome (Index of general cortical thinning)	Baseline, Month 12, Month 27	- Index of general cortical thinning (MRI)
Change in cognitive battery, secondary outcome (Spatial Pattern Separation Task)	Baseline, Month 6, Month 12, Month 21, Month 27	- Spatial Pattern Separation Task
Change in cognitive battery, secondary outcome (Navigation Test Suite)	Baseline, Month 6, Month 12, Month 21, Month 27	- Navigation Test Suite
Change in cognitive battery, secondary outcome (Stroop Color and Word Test - Prague Version)	Baseline, Month 6, Month 12, Month 21, Month 27	- Stroop Color and Word Test - Prague Version (color-word/dots interference)
Change in cognitive battery, secondary outcome (Digit Span: Digit forward, subscale of WAIS-WMI)	Baseline, Month 6, Month 12, Month 21, Month 27	- Digit Span: Digit forward (subscale of WAIS-WMI)
Change in imaging, secondary outcome (Post-stroke lacune volume)	Baseline, Month 12, Month 27	- Post-stroke lacune volume (MRI)
Change in biomarker analysis, secondary outcome (Neurofilament light chain)	Baseline, Month 12, Month 27	- Neurofilament light chain (NFL)

Trial Locations

Locations (1)

Motol University Hospital; 🇨🇿 Praha, Czechia